• Users Online: 233
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 8  |  Issue : 2  |  Page : 74-80

Blood cell activation as an indicator of prothrombogenesis in polycythemia vera: Case control study


1 Department of Physiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
2 Department of Medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq

Correspondence Address:
Dr. Farqad B Hamdan
Department of Physiology, College of Medicine, Al-Nahrain University, P.O. Box 70044, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijh.ijh_10_19

Rights and Permissions

BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative stem cell disease usually combined with JAK2 mutation. Active JAK2 mutation directly promote platelets and granulocytes activation and indirectly initiate endothelial activation. Such interactions can provoke endothelial injury with subsequent release of procoagulant factors. The aim of this study was to understand of this study is to understand the pathophysiology of increased thrombosis in PV in terms of the effect of JAK2V617F gene mutation in relation to the intensity of the neutrophil CD11b and platelet CD62P. SUBJECTS AND METHODS: A group of 53 patients was examined comprised 30 PV patients and 23 with secondary polycythemia. In parallel, 30 aged- and sex-matched, nonsmokers healthy volunteers served as a control group. Hemoglobin level, packed cell volume, white and red blood cells count, mean corpuscular volume, and platelet count were estimated for all the 83 participants. Flow cytometry for the detection of neutrophil CD11b and platelet CD62P were done for all the participants; whereas quantitative polymerase chain reaction technique for the assessment of JAK2 mutation rate was done for the 30 PV patients only. RESULTS: We were able to detect significantly higher neutrophil CD11b and platelet CD62P expressions in PV patients. Within PV, JAK2 mutation rate was significantly higher in those with a history of thrombosis. A positive relationship was demonstrated between the JAK2 mutation rate and each of CD11b and CD62P. CONCLUSION: There is an overexpression of neutrophil CD11b and platelets CD62P in patients with PV which can be considered as a marker of procoagulant activity in blood cells. Active JAK2 mutation directly promote platelets and granulocytes activation and indirectly initiate endothelial activation and in turn endothelium into a proadhesive and procoagulant surface.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed296    
    Printed4    
    Emailed1    
    PDF Downloaded28    
    Comments [Add]    

Recommend this journal